Category

IBTA News

IBTALogo-featured image

IBTA e-News August 2016 released

The IBTA’s monthly e-News has now been released and has been emailed to all subscribers. Some of the highlights from the August issue include: The 10th International Brain Tumour Awareness Week is fast approaching and will be held from Saturday, 22nd October to Saturday, 29th October inclusive. No matter where you live…

Read More

IBTA e-News July 2016 released

[25 July 2016] The IBTA's monthly e-News has now been released and has been emailed to all subscribers.

Some of the highlights from the July issue include:

  • A research study has found that gross total resection (complete tumour removal) extends survival in glioblastoma patients, compared to subtotal (incomplete) resection. A separate study on mice has found that glioma tumour cells left in the brain after removal surgery grow more aggressively than the original tumour.
  • Research published in the British Journal of Cancer has made the unexpected finding that high blood sugar levels are linked to a reduced risk of meningioma.
  • Experiments on mice have shown that glioma cells use fats (fatty acids) as their primary fuel source. It had been previously thought that glucose was the main fuel source for tumour cells. The authors suggest that previous research did not reflect how tumour cells actually function within the brain.
  • Novocure's second generation Optune, a Tumor Treating Fields (TTFields) device, has been approved for use in the United States by the US Food and Drug Administration (FDA).
  • A new version of the UK Cancer Drugs Fund (CDF) comes into effect on 29thJuly 2016. a coalition of 15 leading UK cancer charities previously expressed “deep concern” that the new CDF will ultimately reduce the number of patients receiving vital treatments.
  • The FDA has granted Rare Pediatric Disease Designation for AbbVie’s ABT-414 - an antibody combined with a drug that targets epidermal growth factor receptor (EGFR) - for the treatment of paediatric patients with EGFR-amplified diffuse intrinsic pontine glioma (DIPG).
  • You can read the IBTA e-News July edition online here

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.

To see an archive of existing e-News issues, click here.

IBTA e-News June 2016 released

[1 July 2016] The IBTA's monthly e-News has now been released and has been emailed to all subscribers.

Some of the highlights from the June issue include:

  • "We've reached an inflection point in our fight against cancer," announced US Vice President Joe Biden, whose son died of a brain tumour, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO 2016), held in Chicago in June
  • Two separate studies find out that elderly glioblastoma patients live longer with combined chemotherapy and radiation therapy
  • A clinical trial has shown that a technology that uses microbubble injections combined with an implanted ultrasound device can disrupt the blood-brain barrier in glioblastoma patients, allowing chemotherapy drugs to enter the tumour
  • A research study points to a link between dopamine and glioblastoma growth
  • Results from a phase 1 trial of Toca 511 and Toca FC, a modified virus that carries a gene into tumour cells combined with a drug that targets the modified tumour cells, have shown that patients with recurrent glioblastoma have extended survival
  • Analysis of blood samples from 110 people who went on to develop glioblastoma has indicated that high levels of vitamin E could be a risk factor
  • Clinical trials for immunotherapy in childhood DIPG tumours, and for young people and children with ependymoma are now recruiting patients
  • An observational study has suggested that people with higher levels of education and greater earnings have a greater risk of being diagnosed with a brain tumour
  • You can read the IBTA e-News June edition online here

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.

To see an archive of existing e-News issues, click here.

IBTA e-News May 2016 released

[1 June 2016] The IBTA's monthly e-News has now been released and has been emailed to all subscribers.

Some of the highlights from the May issue include:

  • The World Health Organisation (WHO) has published an updated classification of central nervous system tumours, setting a new standard for brain tumour research, diagnosis and communication..
  • The US Food and Drug Administration (FDA) has given “breakthrough designation” to a poliovirus-based brain tumour immunotherapy, PVS-RIPO, for the treatment of recurrent glioblastoma.
  • The 2016 / 2017 edition of the IBTA’s Brain Tumour magazine will be available for viewing online via the IBTA website from 8th June.
  • A study has concluded that giving radiation therapy in ‘fractionated’ doses, rather than as a single larger dose, does not spare white matter from the late effects of radiation damage.
  • Two published studies have investigated the potential link between mobile phone use and brain tumours: one finding that the increased rates of brain tumour diagnosis seen in recent years cannot be explained by mobile phone use, another finding that tumour formation was increased in mice exposed to mobile phone frequency radiation.
  • Brain Tumor Awareness Month in the USA saw record numbers of people taking part and the Australian Brain Cancer Action Week saw various outreach, educational events and fund-raising activities take place across the country.
  • Clinical trial results have shown that treatment with a cytomegalovirus (CMV) pp65 dendritic cell (DC) vaccine is linked to better than expected survival in glioblastoma patients.
  • You can read the IBTA e-News April edition online here.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.

To see an archive of existing e-News issues, click here.

 

World Health Organisation updates central nervous system tumour classification

Categorising brain tumours[17 May 2016] The World Health Organisation (WHO) has published an updated classification of central nervous system tumours, setting a new standard for brain tumour research and communication between different centers around the world. The revised fifth edition is a major update to the existing 2007 classification and brings the naming and grouping of brain tumours into line with current scientific understanding and technology. For the first time, the new WHO classification combines the genetic information of brain tumours with their histology (the way the tumour looks under a microscope), thus formulating a more accurate concept for how brain tumour diagnoses should be named and structured.

This new classification is the culmination of work by a collaboration of 117 experts from 20 different countries and will allow for more accurate diagnosis, treatment planning and prognosis. With the new classification, brain tumour patients in clinical trials may be stratified into groups that reflect the molecular profile of their tumour, allowing effective targeted treatments to be found more easily. The new classification will also aid researchers by helping them to make more precise analysis of data in the lab, and to accurately compare their results with other institutions.

Within the updated classification, glioblastomas are now organised according to their IDH mutation status, while some entities have been deleted that no longer have diagnostic and/or biological relevance. Newly identified tumour types have been incorporated into the classification and use of the diagnosis “oligoastrocytoma” is now discouraged in favour of astrocytoma or oligodendroglioma. All changes can be found online in the 2016 World Health Organization Classification of Tumors of the Central Nervous System summary.

The IBTA is excited by the publication of the new classification and recognises that it represents a significant step forward in the ongoing journey to improve brain tumour patient treatment and care. The IBTA also extends its gratitude to the many experts whose hard work has brought about the updated classification, which will serve to benefit brain tumour patients all around the world.

Subscribe to IBTA's e-News!